Ney Carter Borges: Effectiveness and Safety of Andexanet alfa in Life-Threatening Factor Xa Inhibitor-Associated Bleeding
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Kei Sakamoto et al. published in JACC Asia:
“In this real-world postmarketing surveillance study evaluated the use of andexanet alfa, a specific reversal agent for factor Xa inhibitors (FXaIs), in patients presenting with life-threatening or uncontrolled bleeding.
A total of 365 Japanese patients were included, with a median age of 80 years, representing a high-risk, elderly population frequently encountered in clinical practice.
Bleeding profile
The majority of cases involved intracranial hemorrhage (71.5%), followed by gastrointestinal bleeding, highlighting the severity of presentations treated with andexanet alfa.
Effectiveness
- 80.9% of patients achieved ‘effective’ or ‘excellent’ hemostasis
- 30-day survival rate: 83.5% (95% CI: 77.4%–88.0%)
These findings demonstrate robust hemostatic efficacy in a critically ill population
Safety profile
- Adverse drug reactions: 17.5%
- Thrombotic events: 8.8% (notably cerebral infarction)
- Rebleeding events: 1.4%
Notably, more than half of adverse events occurred within the first 72 hours, emphasizing the need for close early monitoring.
Clinical interpretation
Andexanet alfa provides rapid reversal of anticoagulation, enabling effective bleeding control.
However, the associated prothrombotic risk requires careful patient selection and thoughtful timing of anticoagulation resumption.
Conclusion
Andexanet alfa is a clinically effective and essential therapeutic option for FXaI-associated major bleeding, with an acceptable safety profile when used under strict monitoring in high-risk patients.”
Title: Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan
Authors: Kei Sakamoto, Miyo Ishihara, Hiroko Kato, Hyosung Kim, Masaki Okuda, Shunsuke Hiroki, Masatoshi Koga, Kazunori Toyoda
Read the Full Article on JACC Asia
More posts featuring Ney Carter Borges on Hemostasis Today.
-
Oct 8, 2026, 14:10Rebecca Akpeloo: PE as an Overlooked Threat in Sickle Cell Disease
-
Oct 8, 2026, 14:05Christina Pohlman: World Thrombosis Day – Raising Awareness of DVT
-
Oct 8, 2026, 13:59Patience Nkabe Odey: What Drives Rhesus D Screening Uptake Among Pregnant Women?
-
Oct 8, 2026, 13:50Todd Rice: ECMO at the Intersection of Anticoagulation and Respiratory Failure
-
Oct 8, 2026, 13:35Manuel Monreal: Why IVC Filter Retrieval Matters for VTE Outcomes
-
Oct 8, 2026, 12:53Hellen Ishikawa-Ankerhold: PhD and Postdoctoral Positions in Advanced Microscopy and Immunothrombosis at LMU Munich
-
Oct 8, 2026, 12:45Pedro Perez: World Thrombosis Day 2026 – Raising Awareness of Women’s VTE Risk
-
Oct 8, 2026, 12:20Berrin Gunaydin: Functional Biomarkers of Iron Deficiency in Pregnancy
-
Oct 8, 2026, 11:45Wolfgang Miesbach: Milvexian After Acute Coronary Syndrome – What LIBREXIA ACS Found